Daily Stock List
Noble Roman's, Inc. (NROM)
The Bowser Report, Marketbeat.com, TaglichBrothers, and Wall Street Resources reported on Noble Roman's, Inc. (NROM), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.
OTCQB-listed, Noble Roman's, Inc. sells and services franchises and licenses for non-traditional foodservice operations and stand-alone take-n-bake locations. The Company’s business model consists of three growth venues: Grocery Take-n-Bake Licensing; Non-Traditional Franchising; and Stand-Alone Franchising. It franchises and licenses under the Noble Roman’s Pizza, Noble Roman’s Take-N-Bake, Tuscano’s Italian Style Subs, and Noble Roman's Craft Pizza & Pub trade names.
Noble Roman's has its corporate headquarters in Indianapolis, Indiana. The Company has awarded franchise and/or license agreements in all 50 U.S. States plus Washington, D.C., Puerto Rico, the Bahamas, Italy, Canada and the Dominican Republic.
Grocery Take-n-Bake Licensing involves licensing of individual Groceries to sell
Noble Roman’s Pizza. This is a component program using Noble Roman’s ingredients - delis assemble pizzas from standard Noble Roman’s ingredients.
Regarding Non-Traditional Venues, these are usually located in a host facility whose principal business is other than foodservice. These facilities can add pizza-focused foodservice as a Revenue Center; as a Facility Draw; and as an Employee Benefit. Example types of locations include Convenience Stores; Walmart® / Retail Centers;
Entertainment Facilities; Bowling Centers; Hospitals; and Military Bases.
Pertaining to Stand-Alone Venues, these are traditional pizzeria locations and Take-n-Bake locations. There is a merging over time between the kinds of Stand-Alone Venues: Live Yeast Dough; Hand-Rolled Breadsticks; and Baking Services.
In October, Noble Roman's announced that it signed an agreement with TMC Franchise Corp. (TMC) to become a Preferred Supplier for their system of franchised Circle K®, Kangaroo Express® and On the Run® convenience store brands in the U.S. This totals around 800 locations.
TMC is part of the Alimentation Couche-Tard, Inc. group. Alimentation is one of the largest operators and franchisors of convenience stores in North America. TMC will communicate Noble Roman's preferred status for pizza-focused foodservice to its existing franchisees and to all new franchise prospects.
Noble Roman's, Inc. (NROM), closed Tuesday's trading session at $0.484, up 0.83%, on 16,346 volume with 8 trades. The average volume for the last 60 days is 48,290 and the stock's 52-week low/high is $0.426/$1.55.
Cumberland Pharmaceuticals, Inc. (CPIX)
Tiny Gems, StockOodles, SmarTrend Newsletters, DrStockPick, PennyOmega, CRWEFinance, PennyToBuck, Bestotc, CRWEPicks, CRWEWallStreet, and StockHotTips reported previously on Cumberland Pharmaceuticals, Inc. (CPIX), and today we choose to highlight the Company, here at the QualityStocks Daily Newsletter.
A specialty pharmaceutical company, Cumberland Pharmaceuticals, Inc. acquires, develops and commercializes branded prescription products. The design of these products is to improve quality of care and address unmet medical needs. Cumberland has a varied product portfolio with an emphasis on the areas of hospital acute care and gastroenterology. Cumberland Pharmaceuticals has its headquarters in Nashville, Tennessee.
The Company also makes its products available to patients globally via select strategic partnerships. Cumberland Pharmaceuticals owns the worldwide rights to all its brands. The four essential elements of the Company’s growth strategy are: expand, acquire, develop, and identify. It is working to maximize its near-term opportunities through building and growing its branded prescription products in the United States.
Cumberland Pharmaceuticals’ product family includes Acetadote® (acetylcysteine) Injection for the treatment of acetaminophen poisoning, and Caldolor® (ibuprofen) Injection, the first injectable treatment for pain and fever approved in the U.S. Products also include Kristalose® (lactulose) for Oral Solution, a prescription laxative, and Vaprisol® (conivaptan) Injection, for the treatment of hyponatremia.
Moreover, the Company’s products include Omeclamox®-Pak for the treatment of H. pylori and duodenal ulcer disease. In early 2011, Cumberland acquired the rights to Hepatoren® (ifetroban) injection, and the Company has initiated clinical development to treat patients suffering from hepatorenal syndrome.
Other product candidates in clinical development include Boxaban® (ifetroban) Oral Capsule for patients suffering from aspirin exacerbated respiratory disease, and Vasculan™ (ifetroban) Oral Capsule for the treatment of systemic sclerosis.
This calendar year, Cumberland Pharmaceuticals and Clinigen Group announced the entrance into a U.S. commercialization agreement for the oncology support drug, Ethyol®. In addition, Cumberland announced a new development program to develop Vasculan™ oral capsules for the aforementioned treatment of systemic sclerosis. Furthermore, Cumberland and Piramal Critical Care announced the launch of a Caldolor® and Vaprisol® co-promotion across the United States.
In September 2016, Cumberland Pharmaceuticals announced that it launched the U.S. promotion of Ethyol® (amifostine) for Injection, the hospital-based product used to treat oncology patients. Ethyol is a Food and Drug Administration (FDA) approved cytoprotective drug indicated to decrease the incidence of xerostomia in patients undergoing post-operative radiation treatment for head and neck cancer. Additionally, it lessens the cumulative renal toxicity associated with the repeated administration of cisplatin in patients with advanced ovarian cancer.
Cumberland Pharmaceuticals, Inc. (CPIX), closed Tuesday's trading session at $4.7442, down 0.12%, on 3,644 volume with 43 trades. The average volume for the last 60 days is 10,504 and the stock's 52-week low/high is $4.20/$6.45.
eCobalt Solutions, Inc. (ECSIF)
We are highlighting eCobalt Solutions, Inc. (ECSIF) today, here at the QualityStocks Daily Newsletter.
Founded in 1988, eCobalt Solutions, Inc. explores for mineral properties in the United States and Canada. Its principal asset is the 100 percent owned Idaho Cobalt Project (ICP). This Project remains the sole, advanced stage, near term, environmentally permitted, primary cobalt deposit in the U.S. eCobalt Solutions has its headquarters in Vancouver, British Columbia.
The Company formerly went by the name Formation Metals, Inc. It changed its name to eCobalt Solutions, Inc. this past August. The Company’s rebrand accurately reflects the present and future direction of eCobalt Solutions as a strong player in the renewable energy and electric vehicle sectors.
eCobalt Solutions’ commitment is to providing a distinct opportunity for consumers to acquire an ethically sourced, environmentally sound, transparent supply of battery grade cobalt salts, secured safely and responsibly in the U.S. Battery grade cobalt salts are essential for the fast-growing rechargeable battery and renewable energy sectors.
eCobalt’s Idaho Cobalt Project (ICP) consists of the Mine /ill (M&M) site positioned in Lemhi County, Idaho, near the town of Salmon, Idaho, as well as the Cobalt Production Facility (CPF). CPF is a stand-alone hydrometallurgical facility expected to be in Southern Idaho. It will process concentrates from the M&M into cobalt, copper, and gold end products. The project is scheduled to produce the equivalent of 1,500 tons of high purity cobalt per annum over a projected mine life of 12.5 years.
On June 21, 2016, commissioning of a Feasibility Study was awarded to Micon International and SNC-Lavalin. eCobalt Solutions stated that Micon International was already familiar with the Idaho Cobalt Project (ICP), acting as due diligence engineers for lenders in the 2011 financing. In addition, SNC-Lavalin has experience in cobalt hydrometallurgical solvent extraction.
In October, eCobalt Solutions announced that it filed and obtained a receipt for a preliminary short form base shelf prospectus with the Securities Commissions in each of the Provinces of Canada except Quebec. The net proceeds from the sale of Securities for cash - unless otherwise specified in a Prospectus Supplement - will be used to complete the development of the Idaho Cobalt Project for commercial production and general corporate purposes.
eCobalt Solutions, Inc. (ECSIF), closed Tuesday's trading session at $0.436, down 4.53%, on 31,148 volume with 20 trades. The average volume for the last 60 days is 60,063 and the stock's 52-week low/high is $0.059/$0.593.
Entia Biosciences, Inc. (ERGO)
SmallCapVoice reported earlier on Entia Biosciences, Inc. (ERGO), and today we report on the Company, here at the QualityStocks Daily Newsletter.
Founded in 2007, Entia Biosciences, Inc. is an emerging leader in the field of Nutrigenomics. It is an authority on the clinical effects of oxidative stress, iron-related disorders, as well as free radical reactions in mammals. The Company is bringing this expertise to the nutraceutical and medical foods markets. Entia identifies, scientifically validates, patents, and commercializes solutions, which address multi-billion dollar markets for health, beauty, and agriculture. OTCQB-listed, Entia Biosciences is based in Sherwood, Oregon.
The Company’s products include GROH® – Ergo Boost for Hair, Scalp, Skin, Nails and Lashes; Total Nutraceutical Solutions® –Natural and Organic Supplements;
Equisano® – a Superfood for Horses; as well as D Is For Dogs® – Supplements for Dog’s.
Entia Biosciences’ growing portfolio of intellectual property (IP) currently encompasses some of the most powerful antioxidants and bio-nutrients occurring in nature. Its ErgoD2 line of Medical Foods provide for the safe daily nutritional management of an array of autoimmune and neurodegenerative diseases. ErgoD2's ingredients are natural food-based dietary ingredients proven effective in helping to manage specific disease or dysfunctions.
Entia Biosciences’ ErgoD2® technology aims to treat anemia through stabilizing iron levels, reducing inflammation, and boosting the internal antioxidant system. ErgoD2®is a proprietary pharmaceutical grade organic compound from whole food. It contains the micro-nutrients L-Ergothioneine, an amino acid with a dedicated transporter (SLC22A4), and Ergocalciferol (vitamin D2).
These nutrients are naturally enhanced and concentrated to therapeutic levels using the Company’s patented technology. At the core of this technology are the abovementioned L-Ergothioneine and Ergocalciferol. In clinical studies conducted by Entia Biosciences in diabetes and chronic kidney disease, these have been shown to stimulate iron export from the cell.
Recently, Entia Biosciences Founder and Chief Science and Technology Officer, Dr. Marvin Hausman, reported better-than-expected preliminary results in Entia’s chronic kidney disease study taking place on the island of Bonaire. Statistical analysis of the preliminary study results indicates, at a 95 percent confidence level, that three out of four consumers could reasonably expect a 10 percent increase in filtration rate.
Dr. Hausman stated, “Our preliminary results exceeded our expectations and represent new hope for patients facing the challenge of stage 2,3, or 4 CKD.” In addition, Entia Biosciences is conducting an additional study that is underway in Colombia.
Entia Biosciences, Inc. (ERGO), closed Tuesday's trading session at $0.05, even for the day. The average volume for the last 60 days is 5,372 and the stock's 52-week low/high is $0.02/$0.099.
ImmuDyne, Inc. (IMMD)
PennyStocks24, Buzz Stocks, Planet Penny Stocks, Penny Pick Finders, SecretStockPromo, PennyStockProphet, and StockOnion reported on ImmuDyne, Inc. (IMMD), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.
ImmuDyne, Inc. is a health, wellness and skincare company that is commercializing a portfolio of proprietary topical and orally delivered products. These rely on ImmuDyne’s patented and pure Yeast Beta Glucan ingredients. The Company has developed proprietary topical and oral products and a proprietary natural delivery technology with several new market opportunities. Additionally, ImmuDyne manufactures and sells yeast beta-1,3/1,6 glucan for oral and topical uses. ImmuDyne has offices in Mt. Kisco, New York; Tampa, Florida; and Florence, Kentucky.
Via a highly complex, proprietary process, which employs best-in-class technology, ImmuDyne can extract highly purified beta-1,3/1,6-D-glucan from the cell walls of Saccaharomyces cerevisiae. The Company says that it is well-established in the scientific community that beta-glucans are strong activators of the innate immune response. Recent studies indicate that yeast beta-1,3/1,6-D-glucans can also activate adaptive immune responses.
ImmuDyne’s products include iNR Wellness™. iNR Wellness is a nutritional supplement. It naturally supports the immune system with PURACERE™ and a vitamin C complex.
Moreover, products include iNR Wellness MD. This is a nutritional supplement. It naturally empowers one’s immune system with PURACERE™, IP-6, and a vitamin C complex.
ImmuDyne’s strategy is to create new market spaces within the wellness industry through the launch of clinically researched, doctor recommended immune support products and services. Its corporate vision is to establish an international communications platform that will educate consumers about the importance of immune health and the clinically proven health benefits of PURACERE™ and NAYAD®.
in October 2015, ImmuDyne announced that it entered into a semi-exclusive marketing agreement with Inate Scientific, LLC. This is to launch a complete skin care regime that will be based primarily on strategic ingredients provided by ImmuDyne. ImmuDyne owns 78.16667 percent percent of Inate Scientific and has a 51 percent voting interest in the company.
This past September, ImmuDyne announced the signing of a definitive agreement with Pilaris Laboratories, LLC, for a sole and exclusive global license to commercialize the patented PilarisMax line of hair loss products. Pilaris was founded by two well-known dermatologists, Steven D. Shapiro M.D. and Michael T. Borenstein M.D. Ph.D. after 5 years of clinical research on topical dihydrotestosterone (DHT) inhibitors.
ImmuDyne, Inc. (IMMD), closed Tuesday's trading session at $0.24, down 11.37%, on 20,144 volume with 14 trades. The average volume for the last 60 days is 57,921 and the stock's 52-week low/high is $0.06/$0.395.
Singlepoint, Inc. (SING)
The QualityStocks Daily Newsletter would like to spotlight Singlepoint, Inc. (SING). Today, Singlepoint, Inc. closed trading at $0.009, even for the day, on 228,190 volume with 9 trades. The stock’s average daily volume over the past 60 days is 503,975, and its 52-week low/high is $0.0046/$0.018.
Singlepoint, Inc. and marketing provider, today announces an extension of its marketing agreement with RedFynn Technologies, a point of sale and business solutions provider. The collaboration that began with a strategic sales and marketing agreement between the two entities in November, 2014, has become a conduit of business development and expansion opportunities for SinglePoint. SinglePoint's suite of solutions includes applications specifically designed for the unique needs of the non-profit community. These products enable organizations to conduct business transactions, accept donations, and engage in targeted communication campaigns - via mobile phone or tablet.
Singlepoint, Inc. (SING) provides mobile technology and marketing solutions that enable companies, nonprofits and religious organizations to conduct business transactions, accept donations, and engage in targeted communication via mobile devices. Through diversification of its own model, the company is also leveraging its core technology to expand into the mobile auctions and daily fantasy sports markets.
SING currently has two fundraising solutions. Text2Bid is an interactive way to increase auction revenues. The technology makes it easy for people to bid in auctions from any text or web-enabled phone. Donate by Text allows nonprofits to securely collect one-time or recurring donations via text. This capability creates a personal experience for the donors, and enables ongoing communication between the donor and nonprofit or event sponsor.
SING's payment solutions include point-of-sale (POS) terminals, loyalty programs, payment processing, phone services and financing. Pay by Text™ enables a business to accept payment transactions and, in essence, turns the user's mobile phone into a point-of-sale device. Operating on the same platform as mobile marketing, Pay by Text is designed to increase revenues, raise the average per-transaction amount, and create a fast, easy and hassle-free method of payment.
As part of its diversification and expansion strategy, SING recently acquired an interest in DraftFury (www.draftfury.com), a company that offers skill-based NBA, NFL and MLB daily fantasy sports (DFS) contests. DraftFury is known for its innovative offerings and originality, and is the first cash-flow-positive DFS enterprise. This transaction places SING in a multi-billion dollar industry expected to generate entry fees of $14.4 billion in 2020. Under the guidance of a leadership team well-versed in technology, engineering, marketing and raising capital, SING anticipates a strong foothold in its chosen markets. Disclaimer
Singlepoint, Inc. Company Blog
Singlepoint, Inc. News:
SinglePoint, Inc. Expands Collaboration with RedFynn Technologies, Announces Partnership with United Way of Mesa
Singlepoint, Inc. (SING) Featured Again on MoneyTV with Donald Baillargeon, Oct 28
Singlepoint, Inc. (SING) to be Featured on MoneyTV with Donald Baillargeon, 10/21
Medical Transcription Billing, Corp. (MTBC)
The QualityStocks Daily Newsletter would like to spotlight Medical Transcription Billing, Corp. (MTBC). Today, Medical Transcription Billing, Corp. closed trading at $0.83, off by 7.56%, on 12,000 volume with 15 trades. The stock’s average daily volume over the past 60 days is 14,314, and its 52-week low/high is $0.678/$1.78.
Medical Transcription Billing, Corp. will release its third quarter financial results for the three months ended September 30, 2016, before the market opens on Thursday, November 10, 2016. The Company will follow with a conference call for investors on November 10 at 8:30 a.m. EDT to review highlights of its quarterly results and discuss its business outlook, recent MediGain acquisition and other matters. The call can be accessed by dialing 844-802-2438, or 412-317-5131 for international callers, and then referencing "MTBC Third Quarter 2016 Earnings Call." An audio webcast of the call will be available until December 31, 2016 on MTBC's investor relations website at ir.mtbc.com.
Medical Transcription Billing, Corp. (MTBC) is a healthcare information technology (IT) company that provides its fully integrated suite of proprietary web-based solutions and related business services to a diverse field of healthcare individuals and entities specializing in more than 63 areas and spanning 40 U.S. states.
The company went public in July 2014, at which time it also acquired three competitors. Since then, MTBC has steadily expanded its portfolio with seven additional acquisitions of competing healthcare IT companies, the most recent of which – and largest to-date - is Texas-based medical billing company, MediGain, LLC.
Today, MTBC is an award-winning company whose Software-as-a-Service (SaaS) platform helps healthcare providers increase revenues, fine tune their clinical and business decision making, reduce administrative burdens, streamline workflows, and reduce operating costs.
Its current products - electronic health records, practice management, patient engagement and the mHealth app – are fully integrated with core services that include medical billing services, value-added services, consultancy services, medical transcription, scribe services, and business intelligence. Notably, the standard fee for its comprehensive platform is calculated as a percentage of a practice's healthcare-related revenues, and is among the lowest in the industry.
MTBC is ranked among the Deloitte Technology Fast 500 (2009, 2010, 2011, 2012), is a Microsoft® Certified Partner, and has been awarded the Surescripts® White Coat of Quality, while its mHealth app – available for smartphone and tablet devices - is ranked No. 1 on Apple Store and Google Play as the most downloaded app for ICD 9 to ICD 10 conversion.
As a reputable IT provider for the healthcare industry, MTBC has built a client base of thousands of doctors. As a way of thanking them for their loyalty, MTBC recently launched its Client Loyalty Program in which it is awarding 100 shares of its publicly traded common stock to its providers and 1,000 shares for referring other physician practices. New MTBC clients are also eligible to participate and receive awards. Disclaimer
Medical Transcription Billing, Corp. Company Blog
Medical Transcription Billing, Corp. News:
MTBC to Announce Third Quarter 2016 Financial Results and Host Conference Call on November 10
MTBC Achieves Corporate Milestone With Its Most Recent Strategic Acquisition
MTBC Announces the Closing of Its Largest Acquisition to Date
Dominovas Energy Corp. (DNRG)
The QualityStocks Daily Newsletter would like to spotlight Dominovas Energy Corp. (DNRG). Today, Dominovas Energy Corp. closed trading at $0.0016, up 14.29%, on 30,601,343 volume with 79 trades. The stock’s average daily volume over the past 60 days is 23,722,422 and its 52-week low/high is $0.001/$0.083.
Dominovas Energy Corp. (DNRG) is an energy solutions company dedicated to bringing clean, sensible and reliable power to areas of the world that lack this precious commodity. Recognizing the incredible growth and profit opportunities of the green and alternative energy markets, Dominovas Energy defined a sustainable deployment model to take a leading position among alternative green energy solutions providers.
At the heart of Dominovas Energy’s Fuel Cell Division is a revolutionary energy solution powered by the RUBICON™ Series Solid Oxide Fuel Cell (SOFC) Technology. Invented by inventor, scholar, professor and visionary Dr. Shamiul Islam, RUBICON™ achieves more than 50% fuel-to-electricity efficiency, providing cost effective, clean, significantly-reduced emissions with silent operations in 100kW to multi-megawatt power arrays. The proprietary system is capable of reforming and converting multiple fuel stocks, and is expected to become the “PLATINUM Standard” by which all other fuel cell technologies are measured.
In early 2014, Dominovas Energy was acquired by Western Standard Energy Corp. in a merger transaction in which Dominovas Energy was the emerging entity. Per the acquisition, Dominovas Energy obtained Western Standard’s 49.25% ownership of award-winning renewable energy company Pro Eco Energy Ltd. Pro Eco Energy provides award-winning heating and cooling systems for commercial and public buildings, delivering the newest alternative energy technologies for energy efficient HVAC systems in a timely and cost-competitive manner.
Dominovas Energy intends to build and own fuel cell utilities worldwide, joining the ranks of some of the world’s largest and most well-known companies that are already taking advantage of the vast opportunities of fuel cell systems. The RUBICON™ is far superior to any other system on the market today, and Dominovas Energy’s ability to produce a fuel cell that accepts multiple fuel sources is invaluable to meet the demands of the mass market. Disclaimer
Dominovas Energy Corp. Blog
Dominovas Energy Corp. News:
Dominovas Energy Presents the Findings of Energy Survey to University of Johannesburg
Dominovas Energy Advances Its Plans for Africa
Dominovas Energy Petitions for Project Grants Through United States Trade and Development Agency
eXp World Holdings, Inc. (EXPI)
The QualityStocks Daily Newsletter would like to spotlight eXp World Holdings, Inc. (EXPI). Today, eXp World Holdings, Inc. closed trading at $4.90, up 3.59%, on 8,914 volume with 16 trades. The stock’s average daily volume over the past 60 days is 33,460, and its 52-week low/high is $0.51/$5.84.
eXp World Holdings, Inc. (EXPI) is the holding company for a number of businesses, most notably eXp Realty LLC, the Agent-Owned Cloud Brokerage™. eXp Realty is a full-service real estate brokerage offering 24/7 access to a suite of collaborative tools, training features and socialization channels designed to meet the unique needs of real estate brokers and agents. By creating a fully-immersive, cloud office environment for real estate professionals, eXp effectively reduces agents' overhead, increases their profits and provides greater service value to consumers.
Through eXp Realty's innovative platform, agents and brokers are afforded the opportunity to earn equity in exchange for production and contributions to company growth. Additionally, eXp features an aggressive revenue sharing program that pays agents a percentage of the gross commission income earned by fellow professionals they recruit into the company. The result is a shared ownership community featuring a synergistic and collaborative group of forward-thinking, entrepreneurial professionals. With the emergence of the internet as the most powerful property marketing and advertising medium, eXp's internet and cloud technologies have helped thousands of consumers find, buy or sell homes without the need for a brick and mortar real estate office.
Since its launch in October 2009, eXp Realty has experienced rapid growth, with brokerage service now offered in 35 U.S. states and Alberta, Canada. In February 2016, the company officially welcomed its 1,000th real estate professional into its family of agent-owners, up from just 467 agents at the end of 2014. Following this achievement, the Agent-Owned Cloud Brokerage claimed a spot among the top 50 real estate brokerages in the United States based on agent count, according to data from RISMEDIA's 2015 PowerBroker 500 Report.
Similarly, eXp Realty generated record financial results during 2015. Following the launch of two new initiatives – including an online lead generation program and a stock compensation plan – the company achieved a 71 percent year-over-year increase in net revenues, recording $22.87 million for the year. As it continues to expand its footprint across North America, eXp Realty will look to leverage its unique agent-owned business model to continue attracting driven, entrepreneurial agents and real estate industry leaders while promoting sustainable financial growth. Disclaimer
eXp World Holdings, Inc. Company Blog
eXp World Holdings, Inc. News:
Eric Burch Real Estate Team Joins eXp Realty
Darren James Real Estate Team Joins eXp Realty in Louisiana
Brent Gove Team Joins eXp Realty in Sacramento
OurPet's Company (OPCO)
The QualityStocks Daily Newsletter would like to spotlight OurPet's Company (OPCO). Today, OurPet's Company closed trading at $0.93, even for the day, on 25,955 volume with 21 trades. The stock’s average daily volume over the past 60 days is 5,532, and its 52-week low/high is $0.6882/$1.06.
OurPet's Company (OPCO) develops, produces and markets various pet accessory and consumable products designed to awaken pets' natural instincts, be it in feeding, playing or waste management. Sold globally through pet specialty retailers, food, drug and mass chains, e-commerce and international channels, the company's products are marketed under a the OurPets®, Pet Zone® and PetTastic® brands with well-known sub-brands such as Play-N-Squeak™, Cosmic Catnip™, Durapet, SmartScoop and Flappy. In total, OurPet's has an intellectual property portfolio featuring more than 160 individual patents, giving the company sustainable access to the pet products industry for the foreseeable future.
In recent years, the U.S. pet products and services market has experienced strong growth, with total sales accounting for approximately $73 billion in 2014, according to a report by Packaged Facts. In 2015, this strong performance is expected to continue, building on the recent rise in related ecommerce purchases, as well as an uptick in dog and cat ownership throughout the country. In order to capitalize on this market performance, OurPet's maintains an ongoing new product development program to continually keep an evolutionary and revolutionary new product pipeline feeding its offerings. In July 2015, OurPet's introduced many new products at the national Super Zoo trade show in Las Vegas such as the Catty Whack®, Designer Diner™/Barking Bistro™ and the Zoom Plume™.
The company's capitalization strategy is guided by a management team of experienced industry professionals dedicated to further strengthening its product portfolio through aggressive development of innovative products. Management has a proven track-record of leveraging deep knowledge in the innovation, technology, distribution and pet markets to successfully push through adverse market conditions to achieve increases in revenue, margins and net income.
OurPet's, through its innovative and extensive line of popular pet products, is in a favorable strategic position to continue building upon its recent market growth. For prospective shareholders, this positioning makes the company an intriguing investment opportunity in the months to come. Look for OurPet's to capitalize on steady market performance moving forward, providing an opportunity for the company to realize strong investor returns in the future. Disclaimer
OurPet's Company Company Blog
OurPet's Company News:
OurPetís Company Reports Record Third Quarter 2016 Results
OurPet's Company CFO to Present at the MicroCap Conference in Philadelphia
Kathleen Homyock of OurPet's Company Presents Smart Technology Trends to Canadian Pet Industry
Today's Top 3
Profitable Trader Authority
Trader Power News
The QualityStocks Public Company Sponsor News